Use of sodium‐glucose cotransporter‐2 inhibitors in France: Analysis of French nationwide health insurance database

Documenti analoghi

• Cost‐effectiveness of sodium‐glucose cotransporter‐2 inhibitors in the treatment of diabetic nephropathy in Japan
  di: Keiko Maruyama‐Sakurai, et al.
  Pubblicazione: (2024)
• Effects of sodium‐glucose cotransporter‐2 inhibitors in myocardial infarction patients: A systematic review and meta‐analysis
  di: Qiufeng Jia, et al.
  Pubblicazione: (2024)
• The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials
  di: Leonardo Buttice, et al.
  Pubblicazione: (2024)
• Association between the body mass index and risk of cardiovascular events in sodium‐glucose cotransporter 2 inhibitor users compared with dipeptidyl‐peptidase 4 inhibitor users: A nationwide cohort study in Korea
  di: Hwa Yeon Ko, et al.
  Pubblicazione: (2025)
• Initiation of sodium‐glucose cotransporter‐2 inhibitors and the risk of infection‐related hospitalisations: A population‐based cohort study
  di: Maria J. Alfonso Arvez, et al.
  Pubblicazione: (2025)